

rTMS et douleurs neuropathiques

Philippe Marque Service de Médecine Physique et de réadaptation CHU Rangueil Toulouse






COMMENT ÇA MARCHE LA RTMS ET LES AUTRES NIBS?



TMS: Transcranial Magnetic Stimulation Principe

Bobine de stimulation

corticales (ICMS) chez l'animal




par la stimulation corticale

Volées corticospinales induites par TMS

Enregistrements épiduraux





Volées corticospinales induites

Burke al. Journal of Physiology (1993) 470: 383-393

Différentes formes de sonde TMS






Sonde papillon 25 mm

Sonde papillon 70 mm








Sonde double cône 70 mm réfrigérée




Champ électrique induit en fonction de la forme de la sonde




Induced Electric Field Profile

Radial Displacement from Coll Centre (mm)



rTMS

rTMS haute fréquence 5Hz




Di Lazzaro et al. Clinical Neurophysiology (2010) 121:464-573c

Berardelli et al. Experimental Brain Research (1998) 122:79-84

rTMS


rTMS basse fréquence 1Hz



(I1-wave)


10 uV

rTMS et Cortex moteur : rôle de la fréquence



Courants galvaniques : tDCS (transcranial Direct Current Stimulation)

- Stimulation anodale: excitation
- Stimulation cathodale : Inhibition







Stimulation placebo

Nitsche et al. 2000

Theta burst Stimulation (TBS)

- Train de 3 coups
- fréquence 50Hz
- toutes les 200 ms (5Hz)
- 80% seuil moteur
- Post-effets + longs pour durée stim très courte < 60 sec (600 pulses (sur M1)) Huang et al. 2005





D'après Moisset et Lefaucheur

REVUE NEUROLOGIQUE 175 (2019) 51-58

EST-CE EFFICACE SUR LES DOULEURS NEUROPATHIQUES?



Clinical Neurophysiology 125 (2014) 2150-2206



Contents lists available at ScienceDirect

Clinical Neurophysiology

journal homepage: www.elsevier.com/locate/clinph

Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS)



Jean-Pascal Lefaucheur ^{a,b,*}, Nathalie André-Obadia ^{c,d}, Andrea Antal ^e, Samar S. Ayache ^{a,b}, Chris Baeken ^{f,g}, David H. Benninger ^h, Roberto M. Cantello ⁱ, Massimo Cincotta ^j, Mamede de Carvalho ^k, Dirk De Ridder ^{l,m}, Hervé Devanne ^{n,o}, Vincenzo Di Lazzaro ^p, Saša R. Filipović ^q, Friedhelm C. Hummel ^r, Satu K. Jääskeläinen ^s, Vasilios K. Kimiskidis ^t, Giacomo Koch ^u, Berthold Langguth ^v, Thomas Nyffeler ^w, Antonio Oliviero ^x, Frank Padberg ^y, Emmanuel Poulet ^{z,aa}, Simone Rossi ^{ab}, Paolo Maria Rossini ^{ac,ad}, John C. Rothwell ^{ae}, Carlos Schönfeldt-Lecuona ^{af}, Hartwig R. Siebner ^{ag,ah}, Christina W. Slotema ^{ai}, Charlotte J. Stagg ^{aj}, Josep Valls-Sole ^{ak}, Ulf Ziemann ^{al}, Walter Paulus ^{e,1}, Luis Garcia-Larrea ^{d,am,1}

Table 1

rTMS studies in chronic neuropathic pain (target: primary motor cortex).

Articles	Number of patients	Target, coil type	Control condition	Stimulation frequency and intensity	Number of pulses/session and number of sessions	Results	Class of the study
LF rTMS of M1 contralateral to	o pain side						
Lefaucheur et al. (2001a)	18	M1, F8c	Sham coil	0.5 Hz, 80% RMT	1000 pulses, 1 session	Non-significant pain relief (4% responders)	III
André-Obadia et al. (2006)	12	M1, F8c	Tilted coil	1 Hz, 90% RMT	1600 pulses, 1 session	Non-significant pain relief (0% responders)	III
Irlbacher et al. (2006)		M1, F8c	Sham coil (2 Hz)	1 Hz, 95% RMT	500 pulses, 5 sessions	Non-significant pain relief (6% responders)	III
	20;						
	control:						
	18)						
Lefaucheur et al. (2006a)	22	M1, F8c	Sham coil	1 Hz, 90% RMT	1200 pulses, 1 session	Non-significant pain relief (14% responders)	II
Saitoh et al. (2007)	13	M1, F8c	Tilted coil	1 Hz, 90% RMT	500 pulses, 1 session	Non-significant pain relief (unknown % responders)	III
Lefaucheur et al. (2008b)	46	M1, F8c	Sham coil	1 Hz, 90% RMT	1200 pulses, 1 session	Non-significant pain relief (9% responders)	II
Recommendation: LF rTMS	of M1 contra	ateral to pain s	side is probably ineffective in neur	opathic pain (Level B)			
HF rTMS of M1 contralateral t	o pain side						
Lefaucheur et al. (2001a)	18	M1, F8c	Sham coil	10 Hz, 80% RMT	1000 pulses, 1 session	Significant pain relief (39% responders)	III
Lefaucheur et al. (2001b)	14	M1, F8c	Sham coil	10 Hz, 80% RMT	1000 pulses, 1 session	Significant pain relief (57% responders)	III
Lefaucheur et al. (2004b)	60	M1, F8c	Sham coil	10 Hz, 80% RMT	1000 pulses, 1 session	Significant pain relief (37% responders and 23%	II
						improvement)	
Khedr et al. (2005b)	48 (active:	M1, F8c	Tilted coil	20 Hz, 80% RMT	2000 pulses, 5 sessions	Significant pain relief (79% responders)	Ι
	28;						
	control:						
André-Obadia et al. (2006)	20) 12	M1, F8c	Tilted coil	20 Hz, 90% RMT	1600 pulses, 1 session	Non-significant pain relief (36% responders and 11%	III
Allule-Obaula et al. (2000)	12	IVII, FOC	Titted con	20 HZ, 90% KIVIT	1000 puises, 1 session	improvement)	III
Hirayama et al. (2006)	20	M1, F8c	Tilted coil	5 Hz, 90% RMT	500 pulses, 1 session	Significant pain relief (50% responders)	II
Irlbacher et al. (2006)	20 27 (active:	M1, F8c	Sham coil (2 Hz)	5 Hz, 95% RMT	500 pulses, 5 sessions	Non-significant pain relief (7% responders)	III
indacher et al. (2000)	19;	WI1, 10C		J 112, JJ/6 KW11	500 puises, 5 sessions	Non-significant pain rener (7% responders)	
	control:						
	18)						
Lefaucheur et al. (2006a)	22	M1, F8c	Sham coil	10 Hz, 90% RMT	1200 pulses, 1 session	Significant pain relief (55% responders)	II
Saitoh et al. (2007)	13	M1, F8c	Tilted coil	5–10 Hz, 90% RMT	500 pulses, 1 session	Significant pain relief (50% responders)	III
André-Obadia et al. (2008)	28	M1, F8c	Sham coil	20 Hz, 90% RMT	1600 pulses, 1 session	Significant pain relief only with posteroanterior orientation	II
		,				of the coil (13% improvement)	
Lefaucheur et al. (2008b)	46	M1, F8c	Sham coil	10 Hz, 90% RMT	1200 pulses, 1 session	Significant pain relief (43% responders)	II
Kang et al. (2009)	11 (spinal	M1, F8c	Tilted coil	10 Hz, 80% RMT	1000 pulses, 5 sessions	Non-significant pain relief (14% improvement)	III
	cord				• ·		
	injury)						
Ahmed et al. (2011)	27 (active:	M1, F8c	Tilted coil	20 Hz, 80% RMT	2000 pulses, 5 sessions	Significant pain relief (up to 2 months after rTMS)	II
	17;						
	control:						
	10)						
André-Obadia et al. (2011)	45	M1, F8c	Sham coil	20 Hz, 90% RMT	1600 pulses, 1 session	Significant pain relief (10% improvement)	II
Lefaucheur et al. (2011b)	59	M1, F8c	Sham coil	10 Hz, 90% RMT	2000 pulses, 1 session	Significant pain relief (36% responders and 22% improvement	II
(1	64	M1 F2			500 miles 10	for "active-sham" condition)	Ţ
Hosomi et al. (2013)	64	M1, F8c	Active coil placed over inactive	5 Hz, 90% RMT	500 pulses, 10 sessions	Significant short-term pain relief (20% responders and 4%	I
			coil combined with electrical			improvement for "active-sham" condition), but no significant	
Letté et al. (2012)	16 (opinal	M1 E9 a	scalp stimulation	10 Hz 00% DMT	2000 pulsos 1 session	cumulative improvement Significant pain relief for hand or log area stimulation for 48 h	ш
Jetté et al. (2013)	16 (spinal	M1, F8c	Sham coil	10 Hz, 90% RMT	2000 pulses, 1 session	Significant pain relief for hand or leg area stimulation for 48 h	111
	cord			(hand area), 110%		(about 15% improvement)	
André-Obadia et al. (2014)	injury) 20	M1, F8c	Sham coil	RMT (leg area) 20 Hz, 90% RMT	1600 pulses, 1 session	Significant pain relief (15% improvement), predictive of	III
mure-Obaula et al. (2014)	20	IVII, FÖC	Siidili Culi	20 AZ, 90% KIVI I	1000 puises, 1 session	subsequent positive outcome of implanted chronic motor	111

Recommendation: definite analgesic effect of HF rTMS of M1 contralateral to pain side in neuropathic pain (Level A)

Table 2

rTMS studies in complex regional pain syndrome type I (target: primary motor cortex).

Articles	Number of patients	Target, coil type	Control condition	Stimulation frequency and intensity	Number of pulses/session and number of sessions	Results	Class of the study
Complex regional pain	syndrome of type I						
Pleger et al. (2004)	10	M1, F8c	Tilted coil	10 Hz, 110% RMT	1200 pulses, 1 session	Significant pain relief (70% responders, but short-lasting effect, <1 h)	III
Picarelli et al. (2010)	22 (active: 11; control: 11)	M1, F8c	Sham coil	10 Hz, 100% RMT	2500 pulses, 10 sessions	Significant pain relief (51% improvement, mostly for affective component of pain)	II

Clinical Neurophysiology 131 (2020) 474–528



Contents lists available at ScienceDirect

Clinical Neurophysiology

journal homepage: www.elsevier.com/locate/clinph

Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014–2018)



Jean-Pascal Lefaucheur ^{a,b,*}, André Aleman ^c, Chris Baeken ^{d,e,f}, David H. Benninger ^g, Jérôme Brunelin ^h, Vincenzo Di Lazzaro ⁱ, Saša R. Filipović ^j, Christian Grefkes ^{k,l}, Alkomiet Hasan ^m, Friedhelm C. Hummel ^{n,o,p}, Satu K. Jääskeläinen ^q, Berthold Langguth ^r, Letizia Leocani ^s, Alain Londero ^t, Raffaele Nardone ^{u,v,w}, Jean-Paul Nguyen ^{x,y}, Thomas Nyffeler ^{z,aa,ab}, Albino J. Oliveira-Maia ^{ac,ad,ae}, Antonio Oliviero ^{af}, Frank Padberg ^m, Ulrich Palm ^{m,ag}, Walter Paulus ^{ah}, Emmanuel Poulet ^{h,ai}, Angelo Quartarone ^{aj}, Fady Rachid ^{ak}, Irena Rektorová ^{al,am}, Simone Rossi ^{an}, Hanna Sahlsten ^{ao}, Martin Schecklmann ^r, David Szekely ^{ap}, Ulf Ziemann ^{aq}

Table 1HF-rTMS of M1 contralateral to pain region in neuropathic pain.

Articles	Number of patients	Target, coil type	Control condition	Stimulation frequency and intensity	Number of pulses/ session and number of sessions	Significant clinical effects of real versus sham condition	Class of the study
Khedr et al. (2015)	30 patients with malignant neuropathic pain (real: 15; sham: 15)	Hand M1 contralateral to pain, F8c (anteroposterior orientation)	Tilted coil	20 Hz, 80% RMT	2000 pulses, 10 sessions	Reduction of pain score at the end of rTMS protocol (49% on VRS and 37% on VAS), up to 2 weeks after the last session (46% on VRS and 36% on VAS); 87–80% responders (>30% pain relief)	II
Ma et al. (2015)	40 patients with postherpetic neuralgia (real: 20; sham: 20)	Homotopic M1 contralateral to pain region, F8c (anteroposterior orientation)	Tilted coil	10 Hz, 80% RMT	1500 pulses, 10 sessions	Reduction of pain score (17% on VAS), up to 3 months after the last session; 50% responders (>50% pain relief)	II
Attal et al., 2016	32 patients with neuropathic lumbar radicular pain (real: 21; sham: 11)	Hand M1 contralateral to pain, F8c (anteroposterior orientation)	Sham coil	10 Hz, 80% RMT	3000 pulses, 3 sessions	Reduction of pain score at the end of rTMS protocol (#60% on VAS), up to 5 days after the last session (#25% on VAS); 43% responders (>30% pain relief)	II
Nurmikko et al. (2016)	27 patients with neuropathic pain of various origins (crossover)	Homotopic M1 contralateral to pain region or an adjacent motor region, F8c (perpendicular to central sulcus)	Occipital stimulation	10 Hz, 90% RMT	2000 pulses, 5 sessions	Reduction of pain score compared to control condition one week after the last session (9–11% on VAS); 30% responders (>30% pain relief)	Π



Cochrane Database of Systematic Reviews

Non-invasive brain stimulation techniques for chronic pain (Review)

O'Connell NE, Marston L, Spencer S, DeSouza LH, Wand BM

Review: Non-invasive brain stimulation techniques for chronic pain Comparison: 1 Repetitive transcranial magnetic stimulation (rTMS) Outcome: 3 Pain: short-term follow-up, subgroup analysis, neuropathic pain participants only

Study or subgroup	Std. Mean Difference (SE)	Std. Mean Difference IV.Fixed,95% CI	Weight	Std. Mean Difference IV,Fixed,95% CI	
l Low-frequency ≤ 1 F André-Obadia 2006	z -0.016296 (0.259415)	_	1.9 %	-0.02 [-0.52, 0.49]	
Lefaucheur 2001b	0.156 (0.162229)	-+-	4.9 %	0.16 [-0.16, 0.47]	
Lefaucheur 2006 (1) 0.37847 (0.21421)		2.8 %	0.38 [-0.04, 0.80]	
Lefaucheur 2008	0.14778 (0.140854)	+	6.5 %	0.15 [-0.13, 0.42]	
Saitoh 2007	-0.169857 (0.332186)		1.2 %	-0.17 [-0.82, 0.48]	
Subtotal (95% Cl Heterogeneity: Chi ² = Test for overall effect:	2.48. df = 4 (P = 0.65); $I^2 = 0.0\%$	6 •	17.3 %	0.15 [.0.02, 0.32]	
2 High-frequency ≥ 5 André-Obadia 2006	Hz -0.066506 (0.259685)		1.9 %	-0.07 [-0.58, 0.44]	
	(-0)41092 (0.191008)		3.5 %	-0.41 [-0.79, -0.04]	
	-03287518 (0.187174)		3.7 %	-0.29 [-0.65, 0.08]	
	-0.383319 (0.105999)		11.5 %	-0.38 [-0.59, -0.18]	
	-2.717609 (0.743356) + +		0.2 %	-2.72 [-4.17, -1.26]	
de Oliveira 2014	-0.33 (0.438776)		0.7%	-0.33 [-1.19, 0.53]	
Defrin 2007 (4)	1.12 (0.642857)		0.3 %	1.12 [-0.14, 2.38]	
-	0.23554 (0.311152)		1.3 %	0.24 [-0.37, 0.85]	
-	0.19336 (0.309779)		1.3 %	0.19 [-0.41, 0.80]	
-	0.18872 (0.309645)		1.3 %	0.19 [-0.42, 0.80]	
-	-0.38726 (0.318223)		1.3 %	-0.39 [-1.01, 0.24]	
Hosomi 2013 (9)	-0.11985 (0.116422)	•	9.5 %	-0.12 [-0.35, 0.11]	
	-0.057109 (0.127547)	-	7.9 %	-0.06 [-0.31, 0.19]	
Jetté 2013	-0.301786 (0.248108)	-+-	2.1%	-0.30 [-0.79, 0.18]	
Jetté 2013	-0.191079 (0.244849)		2.2 %	-0.19 [-0.67, 0.29]	
Kang 2009	0.43402 (0.216454)	+-	2.8 %	0.43 [0.01, 0.86]	
Lefaucheur 2001a	-0.9332 (0.219757)		2.7 %	-0.93 [-1.36, -0.50]	
Lefaucheur 2001b	-0.274478 (0.233036)	-+-	2.4 %	-0.27 [-0.73, 0.18]	
Lefaucheur 2004	-0.344828 (0.091197)	-	15.5 %	-0.34 [-0.52, -0.17]	
Lefaucheur 2006	-0.64827 (0.227633)		2.5 %	-0.65 [-1.09, -0.20]	
Lefaucheur 2008	-0.334132 (0.143948)	+	6.2 %	-0.33 [-0.62, -0.05]	
Nardone 2017	-2.16 (0.72449)	+	0.2 %	-2.16 [-3.58, -0.74]	
Saitoh 2007 (11)	-1.158204 (0.426308)		0.7 %	-1.16 [-1.99, -0.32]	
Saitoh 2007 (12)	-1.110603 (0.419362)		0.7 %	-1.11[-1.93,-0.29]	
Subtotal (95% Cl Heterogeneity: Chi ² = Test for overall effect:) 68.06, df = 23 (P<0.00001); I ² = Z = 7.05 (P < 0.00001)	= 6 6%	82.7 %	-0.28 [-0.36, -0.20]	
Test for overall effect:	90.72. df = 28 (P<0.00001); l² = Z = 5.70 (P < 0.00001) rences: Chi² = 20.19. df = 1 (P =		100.0 %	-0.20[-0.28,-0.13]	
	-4 Favours active	-2 0 2 Favours	4 sham		
(5) S1 (6) PMA (7) SMA (8) M1	il orientation · at baseline in active stim group				
(9) M1 Group B (shar (10) M1 Group A (rea (11) 5Hz					

(12) 10 Hz

Review: Non-invasive brain stimulation techniques for chronic pain Comparison: 1 Repetitive transcranial magnetic stimulation (rTMS) Outcome: 5 Pain: short-term follow-up, subgroup analysis: motor cortex studies only, low-frequency studies excluded

Study or subgroup S	td. Mean Difference (SE)	Std. Mean Difference IV,Random,95% CI	Weight	Std. Mean Difference IV.Random,95% Cl	
1 Single-dose studies André-Obadia 2006-0.00	6506 (0.259685)		3.8 %	-0.07 [-0.58, 0.44]	
André-Obadia 2008 (-D)	1092 (0.191008)	-+-	4.9 %	-0.41 [-0.79, -0.04]	
André-Obadia 2008- 0 228	7518 (0.187174)	-+-	4.9 %	-0.29 [-0.65, 0.08]	
André-Obadia 2011-0.38	3319 (0.105999)	-	6.3 %	-0.38 [-0.59, -0.18]	
Hirayama 2006 -0.3	8726 (0.318223)	-+	3.1 %	-0.39 [-1.01, 0.24]	
Jetté 2013 -0.30	1786 (0.248108)	-+	4.0 %	-0.30 [-0.79, 0.18]	
Jetté 2013 -0.19	1079 (0.244849)	 +	4.0 %	-0.19 [-0.67, 0.29]	
Lefaucheur 2001a -0	9332 (0.219757)	-+	4.4 %	-0.93 [-1.36, -0.50]	
Lefaucheur 2001b -0.23	4478 (0.233036)		4.2 %	-0.27 [-0.73, 0.18]	
Lefaucheur 2004 -0.34	4828 (0.091197)	-	6.5 %	-0.34[-0.52,-0.17]	
Lefaucheur 2006 -0.0	4827 (0.227633)		4.3 %	-0.65 [-1.09, -0.20]	
Lefaucheur 2008 -0.33	4132 (0.143948)	-	5.7 %	-0.33 [-0.62, -0.05]	
Pleger 2004 -0.	38771 (0.21807)		4.4 %	-0.14 [-0.57, 0.29]	
Rollnik 2002 -0.19	0199 (0.199233)	-+-	4.7 %	-0.15 [-0.54, 0.24]	
Saitoh 2007 -1.1	.0603 (0.419362)		2.2 %	-1.11 [-1.93, -0.29]	
Saitoh 2007 -1.19	8204 (0.426308)		2.1%	-1.16 [-1.99, -0.32]	
Subtotal (95% CI)		•	69.6 %	-0.38 [-0.49, -0.27]	
Defrin 2007 Hosomi 2013 (3) -0.09	1.12 (0.642857) 7109 (0.127547)	•	1.1 % 5.9 %	1.12 [-0.14, 2.38] -0.06 [-0.31, 0.19]	
	.9928 (0.116018)	1	6.1%	-0.02 [-0.25, 0.21]	
	3402 (0.216454)	_+_	4.5 %	0.43 [0.01, 0.86]	
Medeiros 2016	-0.57 (0.42602)	_	2.1%	-0.57 [-1.40, 0.26]	
	58 (0.32397959)	_ _	3.0 %	-0.58 [-1.21, 0.05]	
Passard 2007	-1.04 (0.392857)		2.4 %	-1.04 [-1.81, -0.27]	
Tekin 2014	-1.76 (0.334184)	<u> </u>	2.9 %	-1.76 [-2.41, -1.11]	
Yagci 2014	-0.46 (0.408163)	_	2.3 %	-0.46 [-1.26, 0.34]	
Subtotal (95% CI) leterogeneity: Tau ² = 0.2 est for overall effect: Z =	5; Chi² = 44.59, df = 8 (P<0 1.71 (P = 0.086)	0.00001); I ² =82%	30.4 %	-0.34 [-0.73, 0.05]	
est for overall effect: Z =	8; Chi² = 71.66, df = 24 (P< 4.93 (P < 0.00001) es: Chi² = 0.03, df = 1 (P =		100.0 %	-0.37 [-0.51, -0.22]	
	-4 Favours active	-2 0 2 Favours s	4 ham		
 antero-posterior coil medial-lateral coil ori Group B sham followe 					

Summary of findings for the main comparison. Repetitive transcranial magnetic stimulation (rTMS) compared with sham for chronic pain

rTMS compared with sham for chronic pain

Patient or population: adults with chronic pain

Settings: laboratory/ clinic

Intervention: active rTMS

Comparison: sham rTMS

Outcomes	Effect size	Relative and absolute effect (average % improvement (re- duction) in pain (95% CIs) in re- lation to post-treatment score from sham group)* *Where 95%CIs do not cross the line of no effect.	No of partici- pants (studies)	Quality of the evidence (GRADE)
Pain intensity (0 to < 1 week postintervention) measured using visual analogue scales or numerical rating scales	SMD -0.22 (-0.29 to -0.16)	This equates to a 7% (95% CI 5% to 9%) reduction in pain intensity, or a 0.40 (95% CI 0.53 to 0.32) point reduction on a 0 to 10 pain intensi- ty scale.	655 (27)	$\oplus \oplus \odot \odot$ low 1
Disability (0 to < 1 week postin- tervention) measured using self-reported dis- ability/pain interference scales	SMD -0.29, 95% CI -0.87 to 0.29	-	119 (5)	⊕ooo very low²
Quality of life (0 to < 1 week postintervention) measured using Fibromyalgia Im- pact Questionnaire	MD -10.80, 95% CI -15.04 to -6.55	-	105 (4)	⊕⊕⊝⊝ low ³

CI: confidence interval; MD: mean difference; rTMS: repetitive transcranial magnetic stimulation; SMD: standardised mean difference

tDCS compared with sham for chronic pain

Patient or population: adults with chronic pain

Settings: laboratory/ clinic

Intervention: active tDCS

Comparison: sham tDCS

Outcomes	Effect size	Relative effect (average % improvement (re- duction) in pain (95% CIs) in re- lation to post-treatment score from sham group)* *Where 95%CIs do not cross the line of no effect.	No of partici- pants (studies)	Quality of the evidence (GRADE)
Pain intensity (0 to < 1 week postintervention) measured using visual analogue scales or numerical rating scales	SMD -0.43 (-0.63 to -0.22)	This equates to a 17% (95% CI 9% to 25%) reduction in pain inten- sity or a 0.82 (95% CI 0.42 to 1.2) point reduction on a 0 to 10 pain intensity scale.	747 (27)	$\oplus \odot \odot \odot$ very low 1
Disability (0 to < 1 week postin- tervention) measured using self-reported dis- ability/pain interference scales	SMD -0.01, (95% CI -0.28 to 0.26)	-	212 (4)	⊕⊕⊝⊝ low ²
Quality of life (0 to < 1 week postintervention) measured using different scales across studies	SMD 0.66, 95% CI 0.21 to 1.11	-	82 (4)	⊕⊕⊝ ow ²


CI: confidence interval; MD: mean difference; SMD: standardised mean difference; tDCS: transcranial direct current stimulation

Est-ce efficace?

- Recommandation de grade A pour la rTMS dans les douleurs neuropathiques
- Niveau C pour le tDCS et le thetaburst
- Pas de recommandations pour les autres techniques



MÉCANISMES D'ACTION







MODALITÉS PRATIQUES

Où stimuler?

- Cortex moteur primaire :
 - recommandations grade A
- Autres sites :
 - Préfrontal
 - S1 et S2
 - Trop peu d'études pas de recommandations



Où stimuler?



Quel programme?

- Haute fréquence >5 Hz : 10Hz, 20 Hz
- Nombre de coups : 1200 à 2000 pulses par session
- 80% du seuil moteur
- Des trains de 5 à 10s
- Des repos de 20 à 60 s
- 1 à 5 sessions
- Tous les 1 à 6 mois

Combien de temps ça marche?

- 1 session :
 - Début d'effet 1 à 3 jours
 - Durée 5 à 7 jours
- 5 sessions :
 - Jusqu'à 1 mois d'efficacité

Les effets indésirables

• Crise d'épilepsie :

- Cf recommandations européenne


- Migraine
- maux de tête
- Trouble de l'attention
- Acouphènes, phosphènes
- Tous transitoires

QUELLE PLACE DANS LE TRAITEMENT DES DOULEURS NEUROPATHIQUES?



Test pré-implantatoire?

- Essai d'une session
- Si efficace :
 - Diminution 50%
 douleurs dans les 1 à 3 j
- Implantation électrodes épidurales sur le cortex moteur







Fig. 1 Algorithme thérapeutique proposé pour la prise en charge de la douleur neuropathique de l'adulte. TENS : transcutaneous electrical nerve stimulation ; IRSNA : antidépresseur inhibiteur de recapture de la sérotonine et de la noradrénaline ; rTMS : repetitive transcranial magnetic stimulation


NOTRE EXPERIENCE



Share knowledge Paris, France to reduce disabilities July 8-12, 2018







Paris, France

July 8-12, 2018

www.isprm2018.com



Share knowledge o reduce disabilitio Paris, France July 8-12, 2018

Patient charact	eristics
No. of patients	71
Sex (male/female)	43/28
Mean age	56,3
Pain duration mean (years)	6,5
< 2 years	38
> 2 years	33
Pathology_	
Stroke	32
Multiple sclerosis	6
Spinal cord injuries	31
Head trauma	2
Pain Location	
Arm (unilateral / both side)	16/2
Leg (unialtearl / both side)	19/8
Hemibody	18
4 members	7

Results

- ➢ Day 0 : n= 71
- ≻ 48 H: n= 39
- ≻ D1: n=
- ≻ D5: n=
- ➢ M1: n= 47
- ➤ M3: n= 46
- ➢ M6: n= 33



Paris, France July 8-12, 2018

(Results)

- Primary outcome = decreasing of the most intense pain of two points
- Responders







NC ARE PON

0

 \mathbf{N}

2

S

 \mathfrak{S}


D

6 1

Paris, France July 8-12, 2018


Results

Most intense pain evolution





www.isprm2018.com




9,0

B



Share knowledge o reduce disabilitie Paris, France July 8-12, 2018

Results







Paris, France July 8-12, 2018


Results


Most intense pain evolution

Significant
improvement
p<0,05











M6







Paris, France July 8-12, 2018


Results

Pain impact evolution

Significant

p<0,05

improvement



48H

21

35

49

63


7


PDV


NC

25

-25







Conclusion

- rTMS et douleurs neuropathiques : grade A , effet temporaire
- Répétitions de sessions de rTMS et/ou techniques complémentaires (imagerie en miroir ou imagination du mouvement) augmentent la durée d'efficacité
- Il existe de bons répondeurs : 30% dans notre série
- Si bonne réponse mais courte (<1mois) = test préimplantatoire d'une stimulation épidurale du cortex moteur
- > Traitement de 3^{ième} ligne des douleurs neuropathiques